payday loans
payday loans
Skip to content

Accueil Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?
Home spirometry for idiopathic pulmonary fibrosis: ready for prime time? Imprimer Envoyer
Vendredi, 21 Juillet 2017 08:19

The treatment of idiopathic pulmonary fibrosis (IPF) has been transformed with the advent of effective anti-fibrotic therapy [1]. Despite this there remain many challenges confronting those providing day-to-day care to individuals with IPF. Although IPF inevitably progresses over time, the rate at which it does so varies between individuals and is frequently punctuated by life-threatening acute exacerbations or episodes of infection. Additionally, there is currently a lack of measures for determining efficacy of anti-fibrotic treatment for individual patients, which makes decisions to change or persist with therapy difficult. From a clinical trial perspective, the successes of pirfenidone and nintedanib make the development of the next generation of treatments harder. With all future trials expected to be performed on background anti-fibrotic therapy, the rate of decline in FVC seen in trials will be less, thus reducing the window for determining the efficacy of any additional drug [2].


Author:Maher, T. M.


Read Full Article
 

find-us-on-facebook-2

United4LungHealth

image001

waw15-clr-logo2

WCD2015



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2014Ebook

50x50_firefoxsafari_iconGchrome


Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil Home spirometry for idiopathic pulmonary fibrosis: ready for prime time? Top